cancer – Page 4 – media

Celgene Collaboration with Skyhawk for Drug Discovery against Neurological Diseases

To develop small molecules which can target RNA mis-splicing in neurological diseases, Celgene is launching a $60 million collaboration with Skyhawk Therapeutics. Celgene received the option to develop up to five drug molecules for correcting neurological diseases such as Huntington’s disease, amyotrophic lateral sclerosis etc. The $60 million payment includes milestones, license fees and royalties.
- Source: FierceBiotech
- 673
- June 28, 2018
cancer Company Insight neurological
Nanobiotix NBTXR3 in Late Phase Clinical Trial

NBTXR3 is composed of crystalline nanoparticles to amplify the efficacy of radiation therapy. The idea is to administer NBTXR3 as intra-tumoral injections before external beam radiation therapy, thereby increasing the antitumor effect, and thus preparing the patient for surgical resection.
- Source: FierceBiotech
- 611
- June 26, 2018
cancer Clinical Trials radiation therapy
AstraZeneca’s Durvalumab Receives Go-Ahead from DCGI to Market in India

Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
- Source: United News of India
- 2,553
- June 26, 2018
AstraZeneca cancer India New Approvals
Autolus Raises Impressive $150 Million for T-cell Therapy

The IPO has provided the biotech major with the financial bandwidth to aggressively pursue its new generation of CAR-T variants on a broader level, with the advancement of several therapies or the start of clinical trials over the next couple of months.
- Source: FierceBiotech
- 590
- June 25, 2018
acquisition cancer CAR-T therapies Company Insight
Vitamin D Reduces Colorectal Cancer Risk

Previous research claimed that consumption of vitamin D rich foods can reduce the risk factors of colorectal cancer. There was no proper evidence available to link vitamin D levels and colorectal cancer. Now, new research led by the Harvard T.H. Chan School of Public Health, adds convincing evidence to authenticate the link.
- Source: HealthLine
- 2,514
- June 22, 2018
cancer Researches vitamin D
One More Approval for Merck’s Keytruda

On Wednesday, a day after Keytruda got the thumbs up for cervical cancer, the drug was approved for treatment of a rare form of non-Hodgkins lymphoma patients who cancer returned after at least two previous treatment lines. Last year, Keytruda also got an indication for classical Hodgkin lymphoma.
- Source: Fierce Pharma
- 716
- June 15, 2018
cancer Merck New Approvals non-Hodgkin lymphoma
Novartis Prepare Case for Earlier Kisqali Use

On Sunday, at the American Society of Clinical Oncology’s annual meeting, Novartis revealed the final outcome, showing that among patients with HR-positive, HER2-negative breast cancer, adding Kisqali to fulvestrant kept the disease away for eight months longer than fulvestrant alone.
- Source: Ddu
- 613
- June 4, 2018
cancer Company Insight Novartis
Promising Multi-Cancer Screening Test

A research team from Cleveland Clinic in Ohio, US discovered a new test where ten types of cancer could be identified in a patient, well in advance.
- Source: Ddu
- 576
- June 4, 2018
cancer Researches
Viagra and Flu Vaccine Prevents Cancer Regrowth

A research team from the University of Ottawa in Canada revealed a safe and inexpensive treatment by employing Viagra and flu vaccines that might stop cancer revival. Tadalafil (Cialis), sildenafil (Viagra) in combination with Agriflu were used in the research work.
- Source: Ddu
- 715
- May 31, 2018
cancer Clinical Trials flu
Innovative New Method To Fight Cancer

The research study revealed that tumor growth could be reduced by targeting the expression of Beta3-integrin along with microtubule-targeting agents (MTAs) chemotherapy. Beta3-integrin was the better anti-angiogenic target since it was expressed in tumor blood vessels, unlike normal cells.
- Source: Ddu
- 707
- May 29, 2018
cancer Clinical Trials

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.